Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avita Medical, a global medical technology company, has received regulatory approval for ReCell Autologous Spray-On Skin from the Taiwan Ministry of Health.
Subscribe to our email newsletter
In addition to treating burns and other acute wounds, ReCell will also target the growing demand for aesthetic surgery, scar revision and dermal treatments for the aging population. The product focus is on Taiwan’s burgeoning middle class, an affluent and rapidly growing segment of the country’s 23 million people.
Avita Medical said the target market for ReCell includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmetic specialists at private, public and military hospitals and clinics.
Reportedly, Avita Medical will distribute ReCell through Shaw Han, a provider of medical equipment and disposable products for surgical and aesthetic applications in Taiwan. Shaw Han was instrumental in successfully completing the highly complex Taiwanese approval and registration process.
William Dolphin, CEO of Avita Medical, said: “The ReCell technology has strong sales potential in Taiwan where the cosmetics and plastics markets are growing exponentially. Taiwan is a very attractive market for our product.”